Anticonvulsants for preventing mortality and morbidity in full term newborns with perinatal asphyxia
Authors:
- David J EvansDEDavid J Evans
- Mi LeveneMLMi Levene
- 23 April 2001
- reference entry
- Published by Wiley
- No. 2,p. CD001240
Abstract
Background Seizures are common following perinatal asphyxia and may exacerbate secondary neuronal injury by increasing cerebral metabolic demand, causing fluctuations in oxygenation and perfusion, and triggering the release of excitatory neurotransmitters. Long term anticonvulsant therapy may lead to inhibition of brain development and therefore the routine use of anticonvulsant therapy to prevent seizures following perinatal asphyxia needs to be evaluated. Objectives To assess the benefits and harm of administering anticonvulsants to infants of 37 weeks gestation or more following perinatal asphyxia with the primary aims of prevention of death or subsequent severe neurodevelopmental disability and/or the prevention of seizures. Search methods Relevant randomised controlled trials were identified using a combination of electronic database searches (MEDLINE and EMBASE), hand searches and a search of the Cochrane Controlled Trials Registry. Selection criteria All randomised, or quasi‐randomised, controlled clinical trials with reported data comparing the following outcomes: mortality, neurodevelopmental disability, neonatal seizures and adverse events, following anticonvulsant therapy in term infants (37 weeks or more), compared to controls with or without placebo, following perinatal asphyxia. Data collection and analysis Methodological quality and validity of studies were assessed without consideration of the results. Data relevant to the outcome were extracted and analysed. Main results Five randomised or quasi‐randomised controlled trials which met the selection criteria were identified. No studies were of sufficient methodological quality and size to demonstrate a valid, clinically significant change in the risk of mortality or severe neurodevelopmental disability. A meta‐analysis combining three studies comparing barbiturates with conventional therapy following perinatal asphyxia demonstrated no difference in risks of death, severe neurodevelopmental disability, or death or severe neurodevelopmental disability. Authors' conclusions At the present time, anticonvulsant therapy to term infants in the immediate period following perinatal asphyxia cannot be recommended for routine clinical practice, other than in the treatment of prolonged or frequent clinical seizures. Any future studies should be of high quality: randomised control trials with allocation concealment, performance and outcome assessment blinding. Such studies should be of sufficient size, with minimal attrition, to have the power to detect clinically important reductions in mortality and severe neurodevelopmental disability, as the primary outcome measures.Keywords
This publication has 22 references indexed in Scilit:
- Factors Associated with Clinically Significant Perinatal Asphyxia in the Malaysian Neonates: a Case-control StudyJournal of Tropical Pediatrics, 1992
- Pathophysiology and treatment of focal cerebral ischemiaJournal of Neurosurgery, 1992
- 61 HIGH-DOSE PHENOHARGITAL TREATMENT TO PREVENT POSTASPHYXIAL BRIAN DAMAGE: A 6-YEAR FOLLOW-UPPediatric Research, 1991
- Birth asphyxia and hypoxic-ischaemic encephalopathy: incidence and severityPaediatrics and International Child Health, 1991
- Term infant asphyxia in KuwaitPaediatrics and International Child Health, 1990
- The safety and efficacy of alternative anticonvulsant regimes to control newborns seizuresEarly Human Development, 1989
- Early high-dose phenobarbital treatment for prevention of hypoxic-ischemic brain damage in very low birth weight infantsThe Journal of Pediatrics, 1988
- Use of barbiturate therapy in severe perinatal asphyxia: A randomized controlled trialThe Journal of Pediatrics, 1986
- Neonatal Encephalopathy Following Fetal DistressArchives of Neurology, 1976
- Treatment of Cerebral Irritation in the Newborn: Double‐Blind Trial with Chloral Hydrate and DiazepamDevelopmental Medicine & Child Neurology, 1972